Precigen to Participate in the Stifel 2024 Healthcare Conference

PGEN 11.12.2024

Full Press ReleaseSEC FilingsOur PGEN Tweets

About Gravity Analytica

Recent News

  • 01.16.2025 - 43rd Annual J.P. Morgan Healthcare Conference
  • 01.13.2025 - Precigen to Present Plans for Realizing Commercial Vision for PRGN-2012 at the 43rd Annual J.P. Morgan Healthcare Conference
  • 01.09.2025 - Precigen to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Recent Filings

  • 01.16.2025 - 8-K Current report
  • 12.30.2024 - 4 Statement of changes in beneficial ownership of securities
  • 12.30.2024 - EX-99.1 EX-99.1

GERMANTOWN, Md.,Nov. 12, 2024/PRNewswire/ --Precigen, Inc.(Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announcedHelen Sabzevari, PhD, President and CEO ofPrecigen, will participate in a fireside chat onTuesday, November 19, 2024from10:55 to 11:25 AM ETat the Stifel 2024 Healthcare Conferencetaking placeNovember 18 to 19, 2024inNew York.

Precigen Logo (PRNewsfoto/Precigen, Inc.)

Event details can be found onPrecigen'swebsite in the Events & Presentations section atinvestors.precigen.com/events-presentations.

Precigen: Advancing Medicine with Precision®

Precigen(Nasdaq: PGEN) is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target the most urgent and intractable diseases in our core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. Our technologies enable us to find innovative solutions for affordable biotherapeutics in a controlled manner.Precigenoperates as an innovation engine progressing a preclinical and clinical pipeline of well-differentiated therapies toward clinical proof-of-concept and commercialization. For more information aboutPrecigen, visitwww.precigen.comor follow us onLinkedInorYouTube.

Cautionary Statement Regarding Forward-Looking Statements

Some of the statements made in this press release are forward-looking statements. These forward-looking statements are based upon the Company's current expectations and projections about future events and generally relate to plans, objectives, and expectations for the development of the Company's business, including the timing and progress of preclinical studies, clinical trials, discovery programs and related milestones, the promise of the Company's portfolio of therapies, and in particular its CAR-T and AdenoVerse therapies. Although management believes that the plans and objectives reflected in or suggested by these forward-looking statements are reasonable, all forward-looking statements involve risks and uncertainties and actual future results may be materially different from the plans, objectives and expectations expressed in this press release. The Company has no obligation to provide any updates to these forward-looking statements even if its expectations change. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. For further information on potential risks and uncertainties, and other important factors, any of which could cause the Company's actual results to differ from those contained in the forward-looking statements, see the section entitled "Risk Factors" in the Company's most recent Annual Report on Form 10-K and subsequent reports filed with theSecurities and Exchange Commission.

Investor Contact:Steven M. HarasymVice President, Investor RelationsTel: +1 (301) 556-9850investors@precigen.com

Media Contacts:Donelle M. Gregorypress@precigen.com

Glenn SilverLazar-FINN Partnersglenn.silver@finnpartners.com

CisionView original content to download multimedia:https://www.prnewswire.com/news-releases/precigen-to-participate-in-the-stifel-2024-healthcare-conference-302302048.html

SOURCEPrecigen, Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com